From Bio KRX:377220KOSDAQ
프롬바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked17since Sep 11
In Q2 2026, From Bio reported revenue of ₩14.7bn, down 7.5% year on year, and an operating loss of ₩553m. From Bio (프롬바이오) appeared in 0 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 21 with 1 article.
Filing signals 4 quarters of losses Screener
From Bio quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩14.7bn | -7.5% | −₩553m margin −3.8% | −₩1.2bn |
| Q1 2026 | ₩19.2bn | +3.6% | −₩3.3bn margin −17.1% | −₩3.7bn |
| Q4 2025 derived | ₩19.5bn | +12.0% | −₩8.0bn margin −41.0% | −₩10.8bn |
| Q3 2025 | ₩18.3bn | +27.0% | −₩4.4bn margin −24.3% | −₩4.9bn |
| Q2 2025 | ₩15.9bn | -0.5% | −₩3.9bn margin −24.3% | −₩4.6bn |
| Q1 2025 | ₩18.5bn | -4.8% | −₩2.3bn margin −12.5% | −₩2.9bn |
| Q4 2024 derived | ₩17.4bn | +2.0% | −₩9.8bn margin −56.5% | −₩12.2bn |
| Q3 2024 | ₩14.4bn | -3.1% | −₩4.3bn margin −29.8% | −₩4.6bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
From Bio top stories 2 weeks, by number of outlets
- 1
Latest From Bio news Korean headlines
-
MajorExclusive‘건기식 강자’ 프롬바이오, 경영권 매각 추진...‘탈모 신약’ 반전 안 통했다
1 more on this story · 1 outlets
- ‘건기식 강자’ 프롬바이오, 경영권 매각 추진...‘탈모 신약’ 반전 안 통했다조선일보 · Oct 14 06:02
-
프롬바이오, 유휴자산 유동화 추진…차입금 상환
1 more on this story · 1 outlets
- 프롬바이오, 유휴자산 유동화 추진…차입금 상환으로 금융비용 절감바이오타임즈 · Sep 21 11:55
-
프롬바이오 매스틱, 누적 매출 1,700억 원 돌파
1 more on this story · 1 outlets
- 프롬바이오 '매스틱' 누적 매출 1700억원 돌파뉴스핌 · Sep 14 09:34